Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

U.S. stocks are rallying after financial markets worldwide got a shot of adrenaline from an encouraging update on U.S.

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

U.S. stock futures point higher ahead of closely watched CPI report, JPMorgan Chase stock rises on better-than-expected ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...

JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...